Popular GLP-1 medication linked to significant drop in psychiatric hospitalizations for bipolar disorder
Photo: Lucas Vasques / Unsplash
A large-scale Swedish study has revealed that semaglutide, the active ingredient in Ozempic and Wegovy, is associated with a 21% lower risk of psychiatric hospitalization for individuals with bipolar disorder. Researchers suggest the drug's positive impact on inflammation and brain pathways may help stabilize mood, offering a promising new avenue for mental health support.
A large-scale Swedish study has revealed that semaglutide, the active ingredient in Ozempic and Wegovy, is associated with a 21% lower risk of psychiatric hospitalization for individuals with bipolar disorder. Researchers suggest the drug’s positive impact on inflammation and brain pathways may help stabilize mood, offering a promising new avenue for mental health support.